◀ Back to MAPK3

KITLG — MAPK3

Text-mined interactions from Literome

Jeong et al., Endocrinology 2003 : Dexamethasone inhibited SCF induced p38 MAPK activation to near-basal levels and induced MAPK phosphatase-1 expression
Bhanu et al., Blood 2004 : Western blot analyses revealed that SCF was required for phosphorylation of MEK and p44MAPK in this setting, and quantitative polymerase chain reaction demonstrated a significant increase in gamma-globin mRNA
Hue et al., Immunol Lett 2005 (Melanoma, Experimental) : Furthermore, inhibitors of p38 mitogen activated protein kinase ( MAPK ), such as SB203580, blocked enhanced SCF expression, indicating that p38 MAPK activity is required for IL-18 enhanced SCF production
Jacobs-Helber et al., J Biol Chem 1997 (Leukemia, Erythroblastic, Acute) : To elucidate the ability of SCF to affect the erythropoietin signaling pathway, we studied the effect of SCF on EPOR phosphorylation, SHC/ERK-1 activity, and cell proliferation and apoptosis in EPO dependent HCD57 cells ... SCF stimulated SHC phosphorylation and ERK-1 activation independent of the EPOR in cells where the EPOR was down-regulated ; the presence of the EPOR appeared to facilitate SCF activation of SHC and ERK-1
Qu et al., Mol Cell Biol 1997 : Stem cell factor induction of mitogen activated protein kinase activity was also blocked in Shp-2 mutant cells
Sui et al., Blood 1998 : Wortmannin only inhibits MAPK activation induced by EPO but not that by SCF, suggesting that SCF and EPO may activate MAPK through different pathways, which would facilitate synergy